Myasthenia Gravis Therapeutics Pipeline Analysis- Clinical Trials & Results, Patent, Designation, Collaboration

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

Browse Detailed Summary at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

Request Sample Pages: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis/report-sample

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Pre-Purchase Enquiry: https://www.psmarketresearch.com/send-enquiry?enquiry-url=myasthenia-gravis-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

Myasthenia gravis Therapeutics Pipeline Analysis

·         By Phase

·         By Molecule Type

·         By Route of Administration

·         By Company

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

OX-40 Receptor Agonist Therapeutics Pipeline Report Provides a Comprehensive Understanding of the Pipeline Activities Covering All Drug Candidates Under Various Stages of Development

The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.

According to the research findings, most of the drug candidates of OX-40 receptor agonist therapeutics pipeline are being developed as a monoclonal antibody.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample

Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ox40-receptor-agonist-therapeutics-pipeline

In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.

OX-40 Receptor Agonist Therapeutics Pipeline Analysis

·         By Phase

·         By Molecule Type

·         By Route of Administration

·         By Company

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Dry Eye Syndrome Therapeutics Pipeline to Develop with Maximum Drugs Being Derived from Natural Sources

The study analyzed that the dry eyesyndrome therapeutics pipeline comprises approximately 50 drug candidates in different stages of development.

According to the research findings, most of the drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/dry-eye-syndrome-therapeutics-pipeline-analysis/report-sample

InSite Vision (A Sun Pharmaceutical Industries Ltd. company) is using DuraSite technology platform for the development of their drug candidates for the treatment of dry eye syndrome. DuraSite is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=dry-eye-syndrome-therapeutics-pipeline-analysis

The research found that various companies use natural sources for the development of dry eye syndrome therapeutics pipeline that includes, but not limited to, MC2 Therapeutics and RegeneRx Biopharmaceuticals, Inc.

Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAll BioPharma Co., Ltd. and others.

Dry Eye Syndrome Therapeutics Pipeline Analysis

·         By Phase

·         By Route of Administration

·         By Molecule Type

·         By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Myasthenia Gravis Therapeutics Pipeline Analysis- Clinical Trials & Results, Patent, Designation, Collaboration

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myastheniagravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

Request Sample Pages: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis/report-sample

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Pre-Purchase Enquiry: https://www.psmarketresearch.com/send-enquiry?enquiry-url=myasthenia-gravis-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

Myasthenia gravis Therapeutics Pipeline Analysis

·         By Phase

·         By Molecule Type

·         By Route of Administration

·         By Company

Read More

Technological Advancements to Lead the Process of Drug Development for the Treatment of Diabetic Foot Ulcer

The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.

Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where neuropathy dominates and neuroischemic foot where occlusive vascular disease is the main factor.

Diabetic neuropathy, peripheral artery disease and consequent trauma of the foot are the major risk factors for diabetic foot ulcer. The motor and sensory nerve damage can caus muscle weakness, paresis and atrophy in diabetic patients. Diabetic foot ulcer can be assessed by physical examination of the skin for the vascular, neurological, and musculoskeletal systems. Additionally, this examination also involves the assessment of perception of superficial pain, and temperature. Neuropathic disability score is assessed to evaluate the risk of occurrence of neuropathic ulceration.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis/report-sample

Based on route of administration analysis of active drug candidates, it was found that around most of the drug candidates of diabetic foot ulcer pipeline are being developed to be administered by the topical route.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-foot-ulcers-therapeutics-pipeline-analysis

Most of the innovations in technology have been producing novel therapies for the treatment of diabetic foot ulcer. NOx is an advanced wound care technology invented by Edixomed Ltd, that provides the important moist environment, which aids in healing and absorbs wound exudate that generates nitric oxide.

Significant growth in the therapeutic pipeline of diabetic foot ulcer is attributed to increasing collaboration between educational institutes, associations and pharma companies as well as biotech companies. For instance, in March 2016, Microbion Corporation entered into an agreement with Haisco Pharmaceutical Group to develop and commercialize Microbion’s drug candidate for the treatment of chronic wounds in China and related territories.

Some of the key players developing drugs for the treatment of diabetic foot ulcer include Lakewood Amedex, Inc., Edixomed Ltd., CardioVascular BioTherapeutics Inc. and others.

Diabetic Foot Ulcer Pipeline Analysis

o    By Phase

o    By Route of Administration

o    By Molecule Type

o    By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Synovial Sarcoma Therapeutics Pipeline Analysis, Volume Analysis, Segments, Value Share and Key Trends

 The study analysed that the Synovialsarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.

Many technologies such as REOLYSIN technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are being developed that can bring the innovative treatment, which can control the progression of Synovial sarcoma.  ZVex and GLAAS are complementary discovery platforms designed to activate and expand the immune system’s natural ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.

Download Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis/report-sample

The combination of novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=synovial-sarcoma-therapeutics-pipeline-analysis

The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.

Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.

Synovial sarcoma Pipeline Analysis

·         By Phase

·         By Route of Administration

·         By Molecule Type

·         By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Synovial Sarcoma Exhibits Emerging Pipeline with 22 Drug Candidates

The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect...

Read More

Uveitis Therapeutics, Clinical Trials ,Results, Designation, Collaboration Pipeline Analysis

 The study analyzed that the uveitis therapeutics pipeline comprises 33 drug candidates in different stages of development. Uveitis is a type of inflammatory disease that causes swelling and destroys eye tissues. Occurrence of this disease can result in slight reduction of vision or lead to complete vision loss. Uveitis occurs when the middle layer of the eyeball gets inflamed (red and swollen). This layer, known as the uvea, has many blood vessels that nourish the eye. Uveitis can damage vital eye tissue, even resulting in permanent vision loss.

pSivida Corp. is using durasert technology platform for the development of Medidur for the treatment of uveitis. This technology platform is used to provide sustained, localized delivery of drugs to the back of the eye. Durasert products are developed with a drug core surrounded with one or more polymer layers, the permeability of those layers and other aspects of the design of the product, controls the rate and duration of the drug release. However, changing the elements of the design, can help in altering both the rate and duration of release to meet different therapeutic needs. The later generation durasert products and product candidates are injected at the target site, while early generations were surgically implanted.

Download Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis/report-sample

Many companies are involved in the development of drugs for the uveitis therapeutics pipeline, with their products in different phases.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=uveitis-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of uveitis include Aldeyra Therapeutics, Inc., EyeGate Pharmaceuticals, Inc., pSivida Corp. and others.

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Uveitis Exhibits Emerging Pipeline with 30+ Drug Candidates

The study analyzed that the uveitis therapeutics pipeline comprises 33 drug candidates in different stages of development. Uveitis is a type of inflammatory disease that causes swelling and destroys eye tissues. Occurrence of this disease can result in slight reduction of vision or lead to complete vision loss.

Read More

Herpes Simplex Virus (HSV) Infections Therapeutics Pipeline Analysis- Clinical Trials & Results

According to a new research report “Herpes simplex virus infections Therapeutic Pipeline Analysis, - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, Herpes simplex virus infections Therapeutic pipeline currently exhibits a pipeline with 20 drug candidates.

The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development.

 

Insights on pipeline segments

As per the findings of the research, most of the drug candidates are being developed to be administered by oral route.

New innovating technologies offer development of promising drugs

Request to Get the Sample Pages at: 

Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to, Vector based technology platform, AdenoVerse technology platform, Juvari’s technology platform and Nanostat technology platform.

Major companies collaborate for the development of Herpes simplex virus infections Pipeline

The research found that various companies have collaborated for the development of Herpes simplex virus infections pipeline. In June 2014, PaxVax Inc., entered into a research and development collaboration with the University of California to develop a combination vaccine to prevent genital herpes simplex virus infections.

Some of the key players developing drugs for the treatment of Herpes virus simplex infections include Maruho Co., Ltd., NanoBio Corporation, Lumavita AG and others.

Herpes Simplex Virus Infections Therapeutics Pipeline Analysis

By Phase

By Route of Administration

By Molecule Type

By Company

Read More

Systemic Lupus Erythematosus Pipeline to Witness Many Collaborations in the Coming Years

The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues.

The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample

Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=systemic-lupus-erythematosus-pipeline-analysis

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline.

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Systemic Lupus Erythematosus Pipeline Analysis

·         By Phase

·         By Route of Administration

·         By Target

·         By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More